Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13340MR)

This product GTTS-WQ13340MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13340MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12605MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ12426MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ14589MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ12231MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ14587MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ5247MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ13100MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ10501MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW